X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration will explore the potential therapeutic benefits of combination therapy of BBT-877, a novel ATX inhibitor, with anti-PD-1 immunotherapy for the treatment of NSCLC in patients harboring KRAS and P53 (KP) mutations who are resistant to anti-PD-1 blockade.
Lead Product(s): BBT-877,Undisclosed
Therapeutic Area: Oncology Product Name: BBT-877
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Emory University School of Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 28, 2024
Details:
The collaboration will focus on exploring the potential of BBT-877, a novel autotaxin (ATX) inhibitor, as an immuno-oncology treatment for cancer. The two entities will conduct preclinical studies to evaluate the potential of BBT-877 in enhancing anti-tumor immunity.
Lead Product(s): BBT-877
Therapeutic Area: Oncology Product Name: BBT-877
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Colorado School of Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 26, 2024
Details:
Bridge Biotherapeutics and GPCR will pursue joint development and commercialization of the CXCR4-LPA1 inhibitor combination therapy and conducting a multinational phase 2a clinical trial of BBT-877, an autotaxin inhibitor for the treatment of idiopathic pulmonary fibrosis.
Lead Product(s): Undisclosed
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Recipient: GPCR Therapeutics
Deal Size: Undisclosed Upfront Cash: $1.5 million
Deal Type: Licensing Agreement December 14, 2023
Details:
BBT-207, a novel epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) is designed to inhibit the signaling pathway of EGFR with C797S mutations, which arises due to osimertinib (Tagrisso)-resistant mutations in NSCLC.
Lead Product(s): BBT-207
Therapeutic Area: Oncology Product Name: BBT-207
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Details:
BBT-877 is an orally administered autotaxin enzyme inhibitor which is under development as a treatment for various fibrotic diseases such as idiopathic pulmonary fibrosis (IPF).
Lead Product(s): BBT-877
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BBT-877
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2023
Details:
BBT-877 is an orally administered autotaxin enzyme inhibitor which is under development as a treatment for various fibrotic diseases such as idiopathic pulmonary fibrosis (IPF).
Lead Product(s): BBT-877
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BBT-877
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2023
Details:
BBT-401, is a GI-tract restricted small molecule Pellino-1 inhibitor. Pellino serve as scaffold that bind to proteins in inflammatory signaling pathways in various physio-pathological conditions. It is being investiated for inflammatory diseases such as ulcerative colitis.
Lead Product(s): BBT-401
Therapeutic Area: Gastroenterology Product Name: BBT-401
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2023
Details:
BBT-301 inhibits KCa 3.1, a calcium-activated potassium channel at an IC50 (inhibitory concentration 50%) of 6nM, which suggests a competitive channel inhibitory efficacy in the same class of candidates.
Lead Product(s): BBT-301
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: BBT-301
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2022
Details:
The abstract suggests that BBT-176, a novel, 4th generation EGFR-TKI that inhibits the signaling pathway of EGFR with C797S-containing triple mutations has shown its capability of inducing clinical tumor responses in EGFR triple mutation-containing patients.
Lead Product(s): BBT-176,Cetuximab
Therapeutic Area: Oncology Product Name: BBT-176
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2022
Details:
At its latest presentation to investors, Bridge Biotherapeutics shared interim Phase 1 study data of BBT-176 in advanced NSCLC showing that drug candidate was well-tolerated and demonstrated efficacy against EGFR-mutation positive NSCLC.
Lead Product(s): BBT-176,Cetuximab
Therapeutic Area: Oncology Product Name: BBT-176
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 10, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
